The Global Alliance Against Chronic Respiratory Diseases: journey so far and way ahead

Arzu Yorgancioglu¹, Nikolai Khaltaev², Jean Bousquet³, Cherian Varghese⁴

¹Department of Pulmonology, Celal Bayar University, Manisa 45140, Turkey;
²Global Alliance Against Chronic Respiratory Diseases (GARD), Geneva 1224, Switzerland;
³Contrôle les Maladies Chroniques pour un Vieillissement Actif (MACVIA), University Hospital, Montpellier 34090, France;
⁴Department of the Management of Noncommunicable Diseases, World Health Organization, Geneva 1224, Switzerland.

The Global Alliance Against Chronic Respiratory Diseases (GARD) is a voluntary alliance of national and international organizations, institutions, and agencies committed to the vision of “a world where all people breathe freely.”[1,2] Its goal is to reduce the global burden of chronic respiratory disease (CRD).

The GARD initiative was set up to respond to a resolution of the World Health Assembly in May 2000 (Resolution WHA53.17) that emphasized the need to increase awareness of the growing epidemic of CRDs worldwide. A program was begun to design a comprehensive approach to the prevention and control of CRDs.[1,2] The resolution was approved by the General Assembly of World Health Organization (WHO) in 2004. The first meetings of GARD were held at WHO headquarters in Geneva in January and May 2005.[1,3] Its management was established with an Executive Committee, Planning Group, and GARD General Assembly. GARD is a global and multidisciplinary alliance that is charged with helping developing countries; representation from all WHO regions, especially middle and low-income countries, is essential. The structure of GARD management was revised in 2019 to ensure that all major member organizations are represented on the Planning Group.

Jean Bousquet was elected the first Chair, Ronald Dahl the co-Chair, and Nikolai Khaltaev directed the WHO Secretariat. The terms of reference were reviewed with the goals and objectives of GARD. Six working groups were formed; they drew upon existing materials, integrated with WHO initiatives, to develop comprehensive and affordable programs for the management, control, and prevention of CRDs that could be implemented at the country level.

GARD has four strategic objectives: advocacy, partnership, national plans, and surveillance. Its main objective is to promote a comprehensive approach to fight CRD by:

1. Developing a standard way of obtaining relevant data on the burden of disease and risk factors
2. Advocating for action
3. Encouraging countries to implement policies for health promotion and prevention
4. Developing simple and affordable strategies for management

The first General Meeting and GARD launch took place in Beijing in 2006.[4] The prerequisites for becoming a GARD country and the initiatives for establishing a GARD country project were defined. The second prerequisite, that the Ministry of Health of the country is informed about GARD and asked to be involved, is considered as the main difference between GARD and other initiatives.[4,5]

The annual meeting of GARD is a forum for exchanging opinions to improve care for CRDs and to achieve the GARD goals. Thirteen general meetings have taken place in different GARD countries between 2006 and 2019. All posters, presentations, and reports can be found on the link: https://gard-breathefreely.org/resources.

Since its inception, GARD has had many successes, particularly at the country level, which have been reported in many publications.[6-13] Coinciding with these successes, there has been increased recognition of the importance of

---

Access this article online

Quick Response Code: Website: www.cmj.org
DOI: 10.1097/CM9.0000000000000851

Correspondence to: Prof. Arzu Yorgancioglu, Department of Pulmonology, Celal Bayar University, Manisa 45140, Turkey
E-Mail: arzuyo@hotmail.com

Copyright © 2020 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Chinese Medical Journal 2020;Vol(No)
Received: 26-01-2020 Edited by: Qiang Shi
chronic diseases, as demonstrated by the United Nations High Level Meeting on Chronic Diseases held in 2011, during which CRD, along with cardiovascular disease, diabetes, and cancer, were recognized as major health priorities.\textsuperscript{[7]}

Several GARD demonstration projects have been implemented. Some of the most successful include: the Finnish Allergy Programme\textsuperscript{[14,15]} integrated care pathways for airway diseases (AIRWAYS ICPs) on behalf of Director General Santé and Director General (European Union)\textsuperscript{[16,17]} and Mobile Airways Sentinel Network (MASK).\textsuperscript{[18]} MASK was awarded a Good Practice of Director General Santé (European Union) for digitally enabled, patient centered care\textsuperscript{[19]} and was listed in the WHO-International Telecommunications Union booklet, mBreatheFreely\textsuperscript{[20]} as well as the FRESH-air study in developing countries.\textsuperscript{[21-23]}

GARD country projects vary according to country-specific needs and the level of engagement of government health departments. Where government involvement is strong, as in Turkey, Italy, and Portugal, progress has been considerable. In Italy, Portugal, Kyrgyzstan, Russia, and Turkey, GARD has played a significant role in assisting the development of national CRD control programs.\textsuperscript{[6]}

GARD supports WHO in successfully implementing the WHO’s Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013 to 2020.\textsuperscript{[7]} At the last General Meeting, in 2019 in Beijing, GARD adopted the “Beijing Call to Action for Lung Health Promotion” with four key priority areas that conform with the United Nations Sustainable Development Goal 3.4:

1. Advocating for action on CRDs
2. Fostering multi-sectoral action to reduce risk factors for CRDs
3. Strengthening primary health care to achieve universal health coverage for CRDs
4. Supporting research

GARD aims to engage with multiple stakeholders to prioritize sustainable and long-term actions against CRD through “whole of government” and “whole of society” initiatives. These would “mainstream” CRD prevention in all policies and promote inter-sectoral action to address indoor and outdoor air pollution. GARD seeks to engage a range of sectors of society and identify clean-energy strategies to shift away from kerosene, biomass, and biofuel burning, and reduce CO\textsubscript{2} emissions.

GARD seeks to ensure that national Universal Health Coverage benefit packages include CRD services, including respiratory health promotion and prevention, as well as access to essential medicines and technologies, through the adaptation of the WHO Model Lists of Essential Medicines and Essential \textit{in vitro} Diagnostics. It also fosters investigation of the inter-section between social and environmental determinants of health and their impact on the management of CRD with emphasis on the role of populations in conflict.

GARD’s greatest achievement has been its ability to forge collaborative partnerships and develop a shared vision with a large number of parties. Preventing and controlling CRDs and keeping them on the global health agenda will require the ongoing energies of all involved in GARD\textsuperscript{[6,7]} and is a step toward allowing all people to breathe more freely.

\textbf{Conflicts of interest}

None.

\textbf{References}

1. WHO Meeting on the Global Alliance against Chronic Respiratory Diseases (GARD). Geneva: World Health Organization, 2005. Available from: https://www.who.int/respiratory/publications/WHO_NMHC_PCP_05.2_eng.pdf. [Accessed March 23, 2020]
2. Bousquet J, Dahl R, Khaltaev N. Global alliance against chronic respiratory diseases. Allergy 2007;62:216–223. doi: 10.1111/j.1398-9995.2007.01307.x.
3. Global Alliance against Chronic Respiratory Diseases (GARD) General Meeting Report. Geneva: World Health Organization, 2005. Available from: https://www.who.int/respiratory/publications/WHO_NMHC_CPM_05.4_eng.pdf. [Accessed March 23, 2020]
4. Global Alliance against Chronic Respiratory Diseases (GARD) General Meeting Report. Geneva: World Health Organization, 2006. Available from: https://www.who.int/respiratory/publications/Beijing_Meeting_Report_FINAL_layout_26_12_2006.pdf. [Accessed March 25, 2020]
5. Global Alliance against Chronic Respiratory Diseases (GARD) General Meeting Report. Geneva: World Health Organization, 2007. Available from: https://www.who.int/respiratory/publications/MgReport_GMSSeoul_Final.pdf. [Accessed March 25, 2020]
6. Yorgancioglu A, Cruz AA, Bousquet J, Khaltaev N, Mendis S, Chuchalin A, et al. The Global Alliance against Respiratory Diseases (GARD) country report. Prim Care Respir J 2014;23:98–101. doi: 10.4104/pcrj.2014.00014.
7. Mohammad Y, Bedbrook A, To T, McGilhon R, Bárbara C, Melogomes E, et al. Country activities ofGlobal Alliance against Chronic Respiratory Diseases (GARD): focus presentations at the 11th GARD General Meeting, Brussels. J Thorac Dis 2018;10:7064–7072. doi: 10.21037/jtd.2018.12.84.
8. The Global Alliance against Chronic Respiratory Diseases Publications. Available from: https://gard-breathefreely.org/publications/. [Accessed March 25, 2020]
9. Khaltaev N. GARD, a new way to battle with chronic respiratory diseases, from disease oriented programmes to global partnership. J Thorac Dis 2017;9:4676–4689. doi: 10.21037/jtd.2017.11.91.
10. Billo NE. Role of the Global Alliance against Respiratory Diseases in scaling up management of chronic respiratory diseases—summary meeting report. J Thorac Dis 2017;9:2337–2338. doi: 10.21037/jtd.2017.07.55.
11. Forum of International Respiratory Societies. The Global Impact of Respiratory Disease. 2nd ed. Sheffield: European Respiratory Society; 2017.
12. Bousquet J, Agache I, Alberti MR, Anger J, Annesi-Maesano I, Anto JM, et al. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) – EIP on AHA Twinning Reference Site (GARD research demonstration project). Allergy 2018;73:77–92. doi: 10.1111/all.13218.
13. Bousquet J, Hellings PW, Agache I, Bedbrook A, Bachert C, Bergmann KC, et al. ARIA 2016: care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy 2016;6:47. doi: 10.1186/s13601-016-0137-4.
14. Haahntela T, von Hertzen I, Makela M, Hannuksela M. Finnish Allergy Programme 2018–2018—time to act and change the course. Allergy 2008;63:84–95. doi: 10.1111/j.1398-9995.2008.01712.x.

15. Haahntela T, Valovirta E, Bouquet J, Makela M. Allergy Programme Steering Group. The Finnish Allergy Programme 2008–2018 works. Eur Respir J 2017;49:1700470. doi: 10.1183/13993003.00470-2017.

16. Bouquet J, Addis A, Adcock I, Agache I, Agusti A, Alonso A, et al. Integrated care pathways for airway diseases (AIRWAYS-ICPs). Eur Respir J 2014;44:304–321. doi: 10.1183/09031936.00014614.

17. Bouquet J, Barbara C, Bateman E, Bel E, Bewick M, Chavannes NH, et al. AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. Eur Respir J 2016;47:1028–1033. doi: 10.1183/13993003.01856-2015.

18. Bouquet J, Arnauville S, Bedbrook A, Bewick M, Laune D, Mathieu-Dupas E, et al. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl Allergy 2018;8:45. doi: 10.1186/s13601-018-0227-6.

19. Bouquet J, Bedbrook A, Czarlewski W, Onorato GL, Arnauville S, Laune D, et al. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. Clin Transl Allergy 2019;9:16. doi: 10.1186/s13601-019-0252-0.

20. A handbook on how to implement mBreatheFreely for asthma and COPD. World Health Organization, 2017. Available from: https://apps.who.int/iris/handle/10665/274575. [Accessed March 25, 2020]

21. Brakema EA, Tabyshtova A, van der Kleij R, Sooromiaev T, Lious C, Anastasakis M, et al. The socioeconomic burden of chronic lung disease in low-resource settings across the globe - an observational FRESH AIR study. Respir Res 2019;20:291. doi: 10.1186/s12931-019-1255-z.

22. Cragg I, Williams S, Chavannes NH. FRESH AIR: an implementation research project funded through Horizon 2020 exploring the prevention, diagnosis and treatment of chronic respiratory diseases in low-resource settings. NPJ Prim Care Respir Med 2016;26:16035. doi: 10.1038/nppcrmed.2016.35.

23. van Gemert F, Chavannes N, Kirenga B, Jones R, Williams S, Tsiligianni I, et al. Socio-economic factors, gender and smoking as determinants of COPD in a low-income country of sub-Saharan Africa: FRESH AIR Uganda. NPJ Prim Care Respir Med 2016;26:16030. doi: 10.1038/nppcrmed.2016.50.

24. Bouquet JJ, Schulman HJ, Togias A, Erhola M, Hellings PW, Zuberbier T, et al. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clin Transl Allergy 2019;9:44. doi: 10.1186/s13601-019-0279-2.

25. Bouquet J, Schunemann HJ, Togias A, Bachert C, Erhola M, Hellings PW, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol 2020;145:70–80. doi: 10.1016/j.jaci.2019.06.049.

How to cite this article: Yorgancioglu A, Khaltaev N, Bouquet J, Varghese C. The Global Alliance Against Chronic Respiratory Diseases: journey so far and way ahead. Chin Med J 2020;00:00–00. doi: 10.1097/CM9.0000000000000851